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Bariatric surgery, initially intended as a weight-loss procedure, is superior to standard lifestyle intervention and pharmacological 
therapy for type 2 diabetes in obese individuals. Intensive medical management of hyperglycemia is associated with improved 
microvascular outcomes. Whether or not the reduction in hyperglycemia observed after bariatric surgery translates to improved 
microvascular outcomes is yet to be determined. There is substantial heterogeneity in the data relating to the impact of bariatric 
surgery on diabetic retinopathy (DR), the most common microvascular complication of diabetes. This review aims to collate the 
recent data on retinal outcomes after bariatric surgery. This comprehensive evaluation revealed that the majority of DR cases re-
main stable after surgery. However, risk of progression of pre-existing DR and the development of new DR is not eliminated by 
surgery. Instances of regression of DR are also noted. Potential risk factors for deterioration include severity of DR at the time of 
surgery and the magnitude of glycated hemoglobin reduction. Concerns also exist over the detrimental effects of postprandial 
hypoglycemia after surgery. In vivo studies evaluating the chronology of DR development and the impact of bariatric surgery 
could provide clarity on the situation. For now, however, the effect of bariatric surgery on DR remains inconclusive. 
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INTRODUCTION
This article aims to comprehensively review the impact of bar-
iatric surgery on diabetic retinopathy (DR), a microvascular 
complication of type 2 diabetes mellitus (T2DM). Initially, an 
overview of epidemiology, classification, and pathogenesis of 
DR is presented. The relative benefits of medical and surgical 
treatment on glycemic control in T2DM are then briefly dis-
cussed. Following on from this the impact of medical manage-
ment of hyperglycemia on DR is discussed, highlighting con-
cerns about the effect of rapid reductions in blood glucose lev-
els. Finally, the current evidence relating to the impact of bar-
iatric surgery on DR in both the short- and long-term is dis-
cussed in detail. 
DIABETIC RETINOPATHY-EPIDEMIOLOGY 
AND CLASSIFICATION
DR is the most common microvascular complication of T2DM 
worldwide and the leading cause of visual impairment among 
adults aged 20 to 74, with approximately 93 million people 
currently living with DR [1,2]. According to data from the 
United Kingdom Prospective Diabetes Study (UKPDS), 37% 
of patients with T2DM have evidence of retinopathy at the 
time of diagnosis [3]. After two decades of disease, >60% of 
patients with T2DM are expected to have some degree of reti-
nopathy [4]. The principal risk factors for DR are degree and 
duration of hyperglycemia and the presence of comorbid hy-
pertension with or without dyslipidemia [2]. DR is classified as 
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non-proliferative diabetic retinopathy (NPDR) and prolifera-
tive diabetic retinopathy (PDR) disease with reference to 
events occurring in the retinal capillary bed. DR is usually as-
sessed using fundoscopic examiniation of a dilated pupil and 
retinal images can be recorded for future evaluation. Clinical 
evaluation in most centers is based on the Early Treatment Di-
abetic Retinopathy Study (ETDRS) grading scheme [5].
A SUMMARY OF PATHOGENIC 
MECHANISMS
Early DR is usually asymptomatic but this belies structural and 
functional changes in the capillaries and supporting pericytes, 
which cause microvessel aneurysm, occlusion and leakiness 
and the onset of hypoxic injury. Pericytes are perivascular con-
tractile cells that aid in the stabilization and maturation of en-
dothelial cells. Pericyte loss is a hallmark of early DR and typi-
cally precedes endothelial cell loss [6]. Hypoxic stimuli trigger 
the formation of abnormally branched or dilated retinal vessels 
termed intraretinal microvascular abnormalities (IRMAs) in 
NPDR, and neovascularization in PDR [7]. Typically, neovas-
cularization arises at the junction of nonperfused vessels and 
leaky vessels and at the optic disk, and can spread through the 
inner limiting membrane into the vitreous humor. These ves-
sels exhibit increased permeability, raising the risk of vascular 
leakage and vitreous haemorrhage. Vessel permeability can re-
sult in diabetic macular edema (DME). DME, present in up to 
25% of people with diabetes, presents with progressive impair-
ment of visual acuity [8]. A fibrous component develops with 
neovascularization, increasing the risk of tractional retinal de-
tachment [8]. Lipid deposition at the edges of small haemor-
rhages creates hard exudates, which contribute to microcystoid 
degeneration of the retina [9]. 
Microvascular injury and neurodegenerative effects of hy-
perglycemia are considered to be central events in the develop-
ment of DR in cases of chronically poor control of T2DM 
[10,11]. Hyperglycemia accelerates advanced glycation end 
products (AGE) formation. AGEs cross–link with proteins in 
the extracellular matrix, decreasing protein removal and en-
hancing deposition [12]. Activation of the AGE receptor re-
sults in the release of proinflammatory cytokines and growth 
factors, increased oxidative stress, procoagulant activity on en-
dothelial cells and macrophages, proliferation of vascular 
smooth muscle cells and increased extracellular matrix synthe-
sis [10]. Activation of the protein kinase C pathway leads to the 
upregulation of vascular endothelial growth factor [13] and in-
creased production of profibrogenic molecules involved in 
basement membrane synthesis. Cellular sorbitol accumulation 
increases osmotic stress, contributing to vascular damage [14]. 
Nicotinamide adenine dinucleotide phosphate consumption 
in the polyol pathway increases the susceptibility of cells to oxi-
dative stress [1]. During hyperglycemia excess glycolytic fruc-
tose-6-phosphate is directed through the overflow hexosamine 
biosynthesis pathway, the end product of which causes aber-
rant posttranslational modification of cytosolic and nucleic 
proteins. This results in the increased expression of transform-
ing growth factor β1 and plasminogen activator inhibitor-1, 
adversely affecting endothelial cells [15]. Progressive micro-
vascular injury promotes inflammation in the retina involving 
microglial activation and macrophage infiltration into the 
neural retina [8].
The constellation of pathogenic effects of hyperglycemia in 
the retina may be ameliorated by intensified therapies for 
T2DM. The relative impact of intensive medical and surgical 
interventions on control of diabetes and DR is described below.
CONTROL OF T2DM-RELATIVE EFFICACY 
OF MEDICAL AND SURGICAL APPROACHES 
Medical management has traditionally been the mainstay of 
T2DM treatment. However bariatric surgery, originally in-
tended as a weight-loss procedure for very severely obese indi-
viduals (body mass index [BMI] >40 kg/m2), has beneficial ef-
fects on glycemic control in obese patients with T2DM [16-
18]. Typically, successful bariatric surgery results in a >30% 
reduction in total body weight within 1 year, making it the 
most effective treatment for weight loss [19].
Several randomized controlled trials (RCTs) and large case 
control, studies have additionally shown that bariatric proce-
dures are superior to standard lifestyle intervention and phar-
macological therapy for treatment of T2DM in obese patients 
[16-18,20-22]. Though these effects are not permanent, they 
are long lasting and when relapse occurs, good metabolic con-
trol can be achieved with relatively low intensity medical inter-
ventions.
MEDICAL MANAGEMENT: LONG-TERM 
EFFECTS ON DIABETIC RETINOPATHY
Several studies comparing the effect of intensified glycemic 
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control to standard treatment for T2DM have included sec-
ondary endpoints that focus on ophthalmic outcomes. These 
studies are summarized in Table 1. The UKPDS is a large RCT 
comparing intensive and conventional glycemic control in pa-
tients with newly diagnosed T2DM. After 10 years, the inten-
sive treatment cohort achieved a glycosylated hemoglobin 
(HbA1c) of 7.0% compared to 7.9% in the conventional treat-
ment group. The risk of progression of retinopathy was re-
duced by 21% in the intensive treatment group after 12 years 
(n=718). The UKPDS group concluded that for every 1% de-
crease in HbA1c, the relative risk of developing microvascular 
complications decreased by 35% [23]. The Kumamoto study is 
a smaller study comprising of 110 Japanese patients with 
T2DM. Participants had no DR or mild NPDR at baseline and 
were randomized to intensive or conventional insulin therapy. 
After 8 years, this study found that the combined risk reduc-
tion for both the development and progression of DR with in-
tensive treatment was 63% [24].
In the Action in Diabetes and Vascular Disease Preterax and 
Diamicron Modified Release Controlled Evaluation (AD-
VANCE) RCT, participants were randomised to an intensive 
glycaemic control target HbA1c of 47.5 mmol/mol (6.5%) or a 
standard care target of 53 mmol/mol (7%). At the start of the 
study the participants had a mean duration of T2DM of 6 
years. After 4 years, no significant difference in incidence and 
progression of DR was observed between groups (n=1,241) 
[25]. Progression of DR was evaluated in the glycemic control 
arm of the Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) trial (n=2,856). Participants had a mean duration 
of T2DM of 10 years at study entry. Intensive glycaemic con-
trol targeted an HbA1c of 42 mmol/mol (6%), lower than oth-
er studies. After 4 years, retinopathy progression occurred in 
7.3% of the intensive treatment group compared to 10.4% of 
the standard therapy group [26]. The Veteran’s Administration 
Diabetes Trial (VADT) studied 1,792 patients who had a mean 
duration of T2DM of 11.5 years. After a mean follow-up of 5.6 
years, HbA1c was 8.4% in the standard therapy cohort com-
pared to 6.9% in the intensive therapy cohort. There was a 
nonsignificant trend suggesting beneficial effect with inten-
sive-therapy as the increase in DR severity was greater in the 
standard-therapy group (P=0.07). However, there were no dif-
ferences between groups in the incidence of new onset DR or 
in progression to PDR or clinically relevant DME [27].
MEDICAL MANAGEMENT: CONCERNS 
OVER RAPID IMPROVEMENT IN 
HYPERGLYCEMIA
Although overall improvements in glycemic control are associ-
ated with reduced development and progression of DR in the 
Table 1. Major studies comparing intensive medical management to conventional medical management of type 2 diabetes melli-
tus and the associated DR outcomes
Study No. Follow-up, yr New onset DR, % Progression of DR, %
UKPDS [23] 718 12 - Intensive: 38.6
Conventional: 48.7
(P=0.015)
Kumamoto study [24] 110 8 Intensive: 15.4
Conventional: 47.8
(P=0.022)
Intensive: 24
Conventional: 56
(P=0.023)
ADVANCE [25] 1,241 4 Absolute incidence and progression 
Intensive: 14
Conventional: 16.2
(P=0.27)
-
ACCORD [26] 2,856 4 - Intensive: 7.3
Conventional: 10.4
(P=0.003)
VADT [37] 1,791 5.6 Intensive: 42.2
Conventional: 48.9
(P=0.27)
Intensive: 17
Conventional: 22.1
(P=0.07)
DR, diabetic retinopathy; UKPDS, United Kingdom Prospective Diabetes Study; ADVANCE, Action in Diabetes and Vascular Disease Preterax 
and Diamicron Modified Release Controlled Evaluation; ACCORD, Action to Control Cardiovascular Risk in Diabetes; VADT, Veteran’s Ad-
ministration Diabetes Trial.
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long-term, initial worsening of DR has been reported as a con-
sequence of rapid improvement of hyperglycemia. Without 
any change in blood glucose levels, the risk of progression 
from severe NPDR or early PDR to high-risk severe PDR is ap-
proximately 25% over 4 to 6 months. This risk may increase to 
50% with intensive glucose-lowering treatment [28].
Initiation of treatment in patients with type 1 diabetes melli-
tus resulting in a substantial decrease in HbA1c has been asso-
ciated with the development of severe retinopathy, vitreous 
haemorrhage or macular edema within 1 year in patients who 
had little or no retinopathy at baseline [29]. The Diabetes Con-
trol and Complications Trial (DCCT) documented the phe-
nomenon of transient, early worsening of DR with intensive 
glycemic control (n=1,439). At 6, 12, and 18 months progres-
sion by three steps or more on the ETDRS retinopathy scale 
was more common with intensive treatment. The 13.1% of the 
intensive group and 7.6% of the conventional group experi-
enced ‘early worsening,’ defined as the development of soft ex-
udates, IRMAs, or clinically important retinopathy within the 
first 12 months. Approximately half of these patients had re-
covered at the 18-month follow-up. The magnitude of the de-
crease in HbA1c in the first 6 months of treatment was the 
most important risk factor for early worsening. Each percent-
age point drop in HbA1c is associated with a 1.6 times increase 
risk of early worsening. Severity of retinopathy at baseline is 
also associated with the risk of worsening [30]. Proposed 
mechanisms for this phenomenon include a decrease in the 
availability of nutrient substrate, a reduction in the ability of 
retinal circulation to autoregulate and also in increase in 
growth factors [30-34]. Unfortunately, a similar trial has not 
been conducted in T2DM. However, Henricsson et al. [35] did 
find a relationship between the degree of HbA1c improvement 
and deterioration of DR in insulin-treated patients with T2DM 
(n=45) over a 2-year period. This paradoxical deterioration of 
retinal function with improved glycemic control has also been 
observed with intensified insulin treatment in pregnancy. The 
deterioration of background retinopathy correlated with the 
magnitude of glycemic control [36]. In a retrospective 1 year 
study of 165 patients treated with glucagon-like peptide-1 
(GLP-1) receptor agonist (exenatide), overall 29.7% of patients 
treated had new or worsening DR while 19.4% of the cohort 
showed an improvement in pre-existing DR. Interestingly 
there was a significant difference in DR progression rates be-
tween those patients with an improved HbA1c profile (35.3% 
progression rate) versus those in whom HbA1c profile deterio-
rated (6.2% progression rate) [37]. The recently published Li-
raglutide Effect and Action in Diabetes: Evaluation of Cardio-
vascular Outcome Results (LEADER) RCT examined prospec-
tively, with a mean follow-up of 3.8 years, the longer-term ef-
fects of treatment with a GLP-1 analogue on DR. This showed 
no significant impact the incidence of DR (hazard ratio, 1.15; 
95% confidence interval, 0.87 to 1.52), despite evidence of a 
significant reduction in nephropathy [38].
Despite reports of early worsening, the beneficial effects of 
intensive glycemic control are substantial in the long term. By 
inference, this apparently contradictory data is suggestive of 
longer-term adaptation of the retina to lower glycemic levels. In 
the brain, adaptation to hypoglycemia occurs via up-regulation 
of glucose transporter 1 (GLUT1), a glucose transporter pro-
tein, and it may be speculated that an analogous phenomenon 
may be implicated in long-term adaptation in the retina [39]. 
SURGICAL MANAGEMENT OF T2DM AND 
DR OUTCOMES
Since 2012, data has been emerging on the effect of bariatric 
surgery on DR. Data was collected following systematic inter-
rogation of PubMed using the following terms: “bariatric sur-
gery,” “Roux-en-Y gastric bypass,” “gastric bypass,” “bilio-pan-
creatic diversion,” “gastric band,” “vertical sleeve gastrectomy,” 
and “diabetic retinopathy.” This strategy generated 36 results 
and after removal of duplicates, review articles, anecdotal case 
reports, and letters, 13 relevant studies remained. These studies 
are included in the following section and are summarised in 
Table 2.
SURGICAL MANAGEMENT: SHORT TERM 
OUTCOMES
Changes in DR are unpredictable following bariatric surgery. 
Given the reported impact on DR of rapid correction of glyce-
mic control using pharmacological approaches, concerns have 
been raised about the rapid and substantial decreases in blood 
glucose levels that occur after bariatric procedures. Concerns 
also exist about the detrimental effects of episodes of postoper-
ative reactive hypoglycemia [40]. A number of studies investi-
gating the effect of bariatric surgery on retinal outcomes in pa-
tients with T2DM and obesity have been carried out. In the 
Mannheim obesity study (n=30) in 2012, the arteriole-to-ven-
ule ratio, a marker of retinal inflammation/endothelial dys-
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function, improved significantly in obese patients with cardio-
vascular risk factors at 9 months postbariatric surgery [41].
Varadhan et al. [42] conducted a small, retrospective, pilot 
study in 2012 to investigate to effect of vertical sleeve gastrec-
tomy (VSG) or Roux-en-Y gastric bypass (RYGB). Retinal im-
ages were taken presurgery and from 6 to 12 months after sur-
gery. Of those without preoperative DR (n=15), two developed 
new DR. Of those with preoperative DR (n=7), two pro-
gressed, two regressed and three remained stable. Despite the 
small numbers included (n=22), considering 18% of patients 
developed new DR or experienced deterioration of their exist-
ing DR, this pilot study identified the need for further investi-
gation into the implication of bariatric surgery on ophthalmic 
outcomes [42].
A retrospective study with a mean follow up of 1 year was 
conducted by Miras et al. [43] in 2012 (n=67). The main effect 
observed overall was stabilization (91%). A significant im-
provement was observed in a subgroup that had established 
preoperative DR, with 17.8% improving and 3.6% deteriorat-
ing [43].
Johnson et al. [44] conducted a large retrospective study in 
2013 (n=15,951). Less ophthalmic manifestations, defined as 
new diagnosis of blindness in ≥1 eye/laser eye or retinal sur-
gery, were reported in the bariatric surgery group (<0.1%/ 
0.2%) than in the non-surgical group (0.3%/0/6%) after a fol-
low-up of less than 2 years. However caution should be taken 
when interpreting these results as the endpoints examined are 
rare and very severe [44].
Thomas et al. [45] conducted a 12-month retrospective pilot 
analysis in 2014 (n=40). Of those without preoperative DR 
(n=26), 22 still had no evidence of DR postsurgery. The re-
maining four developed minimum background diabetic reti-
nopathy (BDR). Five out of nine participants with minimum 
BDR before surgery deteriorated, while the other four did not 
change. The only participant with moderately severe BDR 
(n=1) progressed to preproliferative diabetic retinopathy 
Table 2. Summary of studies reporting on the surgical management of type 2 diabetes mellitus and the associated DR outcomes
Study No. Follow-up New onset DR Progression of pre-existing DR
Regression of 
pre-existing DR
No change in 
DR status
Varadhan et al. (2012) [42] 22 6–12 mo 2/15 (13%) 2/7 (29%) 2/7 (29%) 16/22 (73%)
Miras et al. (2012) [43] 67 12–18 mo 0/39 (0%) 1/28 (3.6%) 5/28 (17.8%) 61/67 (91%)
Thomas et al. (2014) [45] 38 12 mo 4/26 (15%) 3/12 (25%) 5/12 (42%) 26/38 (68%)
Amin et al. (2016) [46] S: 152
M: 155
3 yr 29/106 (27%) 5/41 (12%) 5/41 (12%) 113/152 (74%) 
Miras et al. (2015) [47] S: 56
M: 21
1 yr S and M: 0/77 (0%)   S: 6/56 (11%)
M: 3/21 (14%)
  S: 6/56 (11%)
M: 1/21 (5%)
  S: 44/56 (78%)
M: 17/21 (81%)
Murphy et al. (2015) [48] 318 334 day 38/218 (17%) 12/100 (12%) 35/100 (35%) 232/318 (73%)
Kim et al. (2015) [49] 20 12 mo 2/12 (16.6%) 7/8 (87.5%) 1/8 (12.5%) 10/12 (83.3%)
Banks et al. (2015) [50] S: 21
M: 24
2 yr Surgery: mean deterioration of 0.24 grades (P=0.135)
Controls: mean deterioration of 0.38 grades (P=0.026)
Zakaria et al. (2016) [53] S: 21
M: 24
13 yr Surgery: 0/20 (0%)
Controls: 1/20 (5%)
- - Surgery: 1/1 (100%) 
Controls: 4/4 (100%)
Abbatini et al. (2013) [54] 33 3 or 5 yr No new incidences 
of DR (32/32)
- - NPDR: 1/1 (100%)
Brynskov et al. (2016) [51] 56 1, 3, 6, and 
12 mo
12 mo: 0/32 (0%)
At 6 mo: 1/32 (3%) 
12 mo: 3/24 (13%)
5/24 (21%) at any 
   follow-up visit
12 mo: 4/24 (17%)
6/24 (25%) at any 
   visit
12 mo: 49/56 
   (87.5%) 
Singh et al. (2015) [52] 150 2 yr No difference between bariatric surgery and intensive medical 
management
86.5% of all 
   participants (n=150) 
Johnson et al. (2013) [44] 15,951 20 mo Surgery vs. Controls
Diagnosis of blindness: <0.1% vs. 0.3%
Laser eye/retinal surgery required: 0.2% vs. 0.6%
DR, diabetic retinopathy; S, surgical; M, medical; NPDR, non-proliferative diabetic retinopathy.
Bariatric surgery and diabetic retinopathy 
359Diabetes Metab J 2016;40:354-364http://e-dmj.org
(PPDR). Two of those with PPDR (n=4) before surgery deteri-
orated, with the other two lost to follow-up [45].
In 2015, Amin et al. [46] conducted a retrospective cohort 
study (n=152) with a mean follow-up duration of 3 years. Re-
sults revealed that the risk of developing sight-threatening DR 
was lower after bariatric surgery (5.7%) compared to non-sur-
gical management (12.1%). However, the absence of evidence 
of DR prior to surgery did not eliminate the risk of developing 
sight-threatening diabetic retinopathy postoperatively [46].
A retrospective case-control study carried out by Miras et al. 
[47] in 2015 revealed that after 1 year there were no significant 
differences in retinal outcomes in participants who underwent 
RYGB compared to medical treatment. In the surgical cohort 
(n=56), 44 participants experienced no change, six improved, 
and six deteriorated. In the medical group (n=21), 17 patients 
experienced no change, one improved, and three deteriorated 
[47].
In 2015, a retrospective observational study conducted by 
Murphy et al. [48] (n=318) revealed that 73% of patients un-
dergoing bariatric surgery had no change in their retinopathy 
grade after a mean of 334 days, a moderate or higher-grade 
retinopathy postoperatively was associated with the magnitude 
of HbA1c reduction, a higher preoperative retinopathy grade 
and male gender.
A small pilot study carried out by Kim et al. [49] in 2015 
(n=20) identified that two out of 12 participants without pre-
operative DR and two out of three participants with mild 
NPDR developed moderate NPDR after surgery. All five par-
ticipants who had moderate NPDR preoperatively experienced 
progression that required further intervention. Although 30% 
of participants who underwent surgery entered remission of 
T2DM, the risk of progression of DR was not eliminated in this 
cohort [49].
Banks et al. [50] conducted a retrospective case-control pilot 
study investigating the progression of DR after RYGB (n=21) 
compared to medical therapy (n=24). DR progressed signifi-
cantly in the medical therapy group, but not in the RYGB 
group. However, there was no significant difference when the 
change in DR scores was compared between groups. Results 
from this study were inconclusive due to heterogeneity of 
group characteristics [50]. 
Brynskov et al. [51] conducted a prospective observational 
study of patients undergoing RYGB or VSG (n=56). Overall, 
six patients experienced worsening of DR at any time within 1 
year, but this only persisted in three patients at 12 months. In 
patients with preoperative DR (n=24), 17 participants experi-
enced no change, three deteriorated, and four improved. For 
those without preoperative DR, one out of 30 participants ex-
perienced a transient worsening at 6 months, but at 12 months 
all 30 were unchanged from baseline. This study concluded 
that retinopathy was clinically stable in the first year after bar-
iatric surgery [51].
The Surgical Therapy And Medications Potentially Eradicate 
Diabetes Efficiently (STAMPEDE) RCT was the first study that 
compared the effects of intensive medical management to bar-
iatric surgery on DR in a large population of patients with 
T2DM (n=150). After 2 years, this study found that RYGB/
VSG did not significantly impact DR. Of all participants, surgi-
cal and medical, 86.5% experienced no change in their reti-
nopathy scoring postoperatively [52]. 
There is significant heterogeneity in the data relating to the 
shorter term impact of bariatric surgery on DR. Some of the 
variability in the data may be explained by differences in the 
incidence of hypoglycaemia, a phenomenon not systematically 
tracked after surgery, or by the type of bariatric procedure per-
formed.
SURGICAL MANAGEMENT: LONG-TERM 
OUTCOMES 
There is a paucity of data on the long-term effects of bariatric 
surgery on DR. A retrospective analysis with a 13-year follow-
up, focusing on the effects of laparoscopic adjustable gastric 
band (LABG) in morbidly obese patients (BMI ≥35 kg/m2), 
with or without diabetes, was carried out by Zakaria et al. [53]. 
Despite the long follow-up, no new cases of DR were recorded 
in the LABG group (n=87) compared with a single case in the 
control goup (n=87). These results indicate that LABG is not 
associated with an increased risk of DR and that outcomes are 
similar to medical treatment in the long term [53]. 
Abbatini et al. [54], evaluated the long-term effects of VSG 
on T2DM severely obese patients retrospectively. Thirty-three 
patients had a 3-year follow-up and 13 of these were also fol-
lowed up at 5 years. No new incidences of DR were reported, 
supporting the concept of bariatric surgery having a preventa-
tive effect on DR development. The single case of preoperative 
DR had not progressed when assessed at the 3-year follow-up 
point [54].
The Swedish Obese Subjects study did reveal that bariatric 
surgery was associated with a decrease in the incidence of mi-
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crovascular complications compared to medical treatment. Af-
ter a mean follow-up of 17.6 years, the incidence in the non-
surgical cohort (n=55) was 41.8 per 1,000 person-years com-
pared to 20.6 per 1,000 person-years in the surgery cohort 
(n=288). Unfortunately the composite end-point incorporated 
renal, retinal and neural endpoints, including whichever com-
plication occurred first. Therefore, it was not possible to speci-
fy the effect of surgical intervention on retinal outcomes in this 
long-term study [17]. 
CONCLUSIONS
The current evidence suggests that the risk of progression of 
pre-existing DR or the development of new DR are not elimi-
nated by bariatric surgery or by the remission of T2DM and 
that surgical intervention may be more beneficial at an earlier 
stage of disease development. In the literature, the majority of 
patients with established DR at the time of surgery had no 
change in their DR grade after surgery. However, instances of 
regression and progression have also been recorded [42-46,48-
55]. This trend was also observed in a systematic review and 
meta-analysis by Cheung et al. [56] that comprised of four pri-
mary studies (n=148). Raw data was sought from all relevant 
studies. In Table 3, data that was successfully obtained was col-
lapsed to determine the number of cases that deteriorated, im-
proved or remained stable depending on DR status at baseline. 
Possible risk factors for progression of DR include severity of 
DR at time of surgery and the magnitude of the reduction of 
Table 3. Summary of DR status at baseline and the associated retinal outcomes after bariatric surgery
Preoperative DR status Deteriorated Stable Improved
No retinopathy (n=443)
   Thomas et al. (2014) [45] 4/26 22/26
   Amin et al. (2016) [46] 29/106 77/106
   Murphy et al. (2015) [48] 38/218 180/218
   Kim et al. (2015) [49] 2/12 10/12
   Zakaria et al. (2016) [53] 0/20 20/20
   Abbatini et al. (2013) [54] 0/32 32/32
   Brynskov et al. (2016) [51] 0/29 29/29
   Total no. (%) 73/443 (16.5) 370/443 (83.5)
Non-proliferative retinopathy (n=179)
   Thomas et al. (2014) [45] 1/10 4/10 5/10
   Amin et al. (2016) [46] 5/42 32/42 5/42
   Murphy et al. (2015) [48] 12/99 52/99 35/99
   Kim et al. (2015) [49] 5/6 1/6 0/6
   Zakaria et al. (2016) [53] 0/1 1/1 0/1
   Abbatini et al. (2013) [54] 0/1 1/1 0/1
   Brynskov et al. (2016) [51] 2/20 15/20 3/20
   Total no. (%) 25/179 (14.0) 106/179 (59.2) 48/179 (26.8)
Proliferative (n=12)
   Thomas et al. (2014) [45] 2/2 0/2 0/2
   Amin et al. (2016) [46] 0/4 4/4 0/4
   Murphy et al. (2015) [48] 0/1 1/1 0/1
   Kim et al. (2015) [49] 2/2 0/2 0/2
   Zakaria et al. (2016) [53] 0/0 0/0 0/0
   Abbatini et al. (2013) [54] 0/0 0/0 0/0
   Brynskov et al. (2016) [51] 1/3 1/3 1/3
   Total no. (%) 5/12 (41.6) 6/12 (50) 1/12 (8.3)
DR, diabetic retinopathy.
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HbA1c. 
The retina is one of the most metabolically active tissues in 
the body. Neural tissue is solely dependent on glucose for en-
ergy rendering the retina more vulnerable than the kidney to 
periods of hypoglycemia. Concerns remain over the effect of 
the rapid decrease of HbA1c after surgery on retinal outcomes. 
This rapid correction of blood glucose, along with postsurgical 
reactive hypoglycemia potentially contributes to worsening of 
DR.
Avoiding postprandial hypoglycemia may prevent hypogly-
cemia detracting from the beneficial effect of removal of hy-
perglycemia. Deepening our understanding of the complex 
pathophysiology of postprandial hypoglycemia after bariatric 
surgery and optimizing appropriate therapy may prove crucial 
in improving retinal outcomes. 
The data on DR are thus much less coherent than the picture 
developing with regard to diabetic kidney disease (DKD). Bar-
iatric surgery is uniformly associated with a reduction in uri-
nary albumin excretion, leading indicating improvement in 
DKD [57]. Parity of the measurements available for DKD is 
not achievable clinically for DR. Therefore, in-depth animal 
studies comparing chronology of DR progression and the im-
pact of surgery could provide clarity on the situation. However, 
for now, whether the effect of bariatric surgery on DR is good, 
bad or both remains inconclusive. 
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